English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 13 July 2022, 14:30 HKT/SGT

Source: Novotech Health Holdings Pte Ltd
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea

SEOUL, S.KOREA, July 13, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval.

SK bioscience and GSK recently announced the successful authorization:

SK bioscience announced that 'SKYCovione(TM),' South Korea's first COVID-19 vaccine candidate adjuvanted with GSK's pandemic adjuvant has been authorized by the Korean Ministry of Food and Drug Safety (KMFDS). South Korea has become one of the few countries in the world to have both a domestically developed COVID-19 vaccine and a treatment.

SKYCovione(TM) is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine with combination of GSK's pandemic adjuvant. The development of SKYCovione(TM) has been supported by funding from the Bill & Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations (CEPI).

The results of the Phase III clinical trial, collected in 4,037 adults over 18-year-old, showed that SKYCovione(TM) induced neutralizing antibody responses, against the SARS-CoV-2 parental strain. The neutralizing antibody titres increased about 33 times compared to before the injection and were 3 times that of AstraZeneca's Vaxzevria(TM), the control vaccine used in the study, 2 weeks after the second dose.

The clinical trial was conducted in cooperation with 16 institutions, including Korea University Guro Hospital and IVI (International Vaccine Institute), a non-profit international organization.

SK bioscience will apply for authorizations at other selected regulatory agencies for distribution of SKYCovione(TM), including through the COVAX Facility and for emergency use listing (EUL) to the World Health Organization (WHO).

SKYCovione(TM) is based on recombinant protein vaccine technology which has been used for development of current vaccines including influenza, hepatitis B, and HPV. SKYCovione(TM) can be stored in normal refrigeration conditions from 2 to 8 degrees Celsius, so it is particularly suitable for use in low-income settings without the need for ultra-cold chain facilities.

The market expects that SKYCovione(TM) will accelerate securing of Korea's vaccine sovereignty and reducing dependence on vaccine imports.

Jaeyong Ahn, CEO of SK bioscience said, "The development of Korea's first COVID-19 vaccine was achieved based on the efforts of the government and members who have been working hard all day and night. We will continue to work with various global organizations based on our own research and manufacturing technologies to preemptively respond to new pandemics."

See full press release here https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=132&

Dr. John Moller, CEO Novotech said, "As the lead CRO managing the Phase lll study in six APAC countries, the entire team at Novotech congratulates SK bioscience for such an outstanding clinical success and subsequent licence approval. Licence approval is the ultimate goal in clinical research and drug development and we are honoured to be part of the process of bringing new life-saving therapies to market. We look forward to working with SK bioscience on further vaccine developments in the near future."

About Novotech

Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Novotech Health Holdings Pte Ltd Releated News
Sept 17, 2022 07:00 HKT/SGT
노보텍,제6회CGTWA 컨퍼런스에서‘2022세포유전자치료제우수상’수상
Sept 16, 2022 10:00 HKT/SGT
Novotech 在第六届细胞与基因治疗世界亚洲会议上荣获 2022 年细胞与基因卓越奖
Sept 16, 2022 10:00 HKT/SGT
Novotech 在第六屆細胞與基因治療世界亞洲會議上榮獲 2022 年細胞與基因卓越獎
Sept 15, 2022 17:00 HKT/SGT
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference
Sept 6, 2022 15:00 HKT/SGT
노보텍, 유럽종양학회 연례학술회의2022 참가 - 아태 지역 종양학 시험 부문 100 % 성장 기록한 새로운 데이터 공개
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575